利特昔替尼真实世界治疗斑秃多部位疗效及早期应答预测因素
单中心回顾性队列纳入89例接受利特昔替尼50 mg/日≥12周的斑秃患者,评估头皮、睫毛、眉毛及甲疗效与安全性。睫毛、眉毛、甲疗效与头皮平行;既往JAK抑制剂暴露是早期应答降低的独立预测因素,未报告严重不良事件。
要点
- 利特昔替尼对头皮、睫毛、眉毛及甲的疗效随时间进展且相互平行。
- 既往JAK抑制剂暴露与早期治疗应答降低独立相关。
- 研究期间未报告严重不良事件,安全性良好。
核心结论
- 既往JAK抑制剂暴露是影响利特昔替尼早期治疗应答的重要因素。
- 睫毛、眉毛和甲的应答与头皮相似。
研究设计与样本
- 单中心回顾性队列研究,连续纳入接受利特昔替尼50 mg每日一次≥12周的斑秃患者。
- 共89例患者,平均年龄25.6±13.9岁,女性占69.7%。
- 在基线及第4、8、12、24、36周评估疾病严重度,系统记录治疗中出现的不良事件,采用多因素logistic回归分析应答与临床预测因素的关联。
主要发现
- 疗效结局呈现时间性进展。
- 睫毛、眉毛和甲中观察到的疗效与头皮平行。
- 多因素分析确定既往JAK抑制剂暴露是早期应答降低的独立预测因素。
- 利特昔替尼安全性良好,研究期间未报告严重不良事件。
临床怎么用
- 真实世界中对斑秃患者使用利特昔替尼50 mg每日一次时,应关注既往JAK抑制剂暴露史以预判早期应答可能降低。
- 评估疗效时需同时关注头皮、睫毛、眉毛和甲的应答情况。
局限性
- 单中心研究。
- 队列限于中国人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effectiveness of ritlecitinib for alopecia areata is unknown in real-world practice. OBJECTIVE: This real-world study aimed to evaluate the effectiveness and safety of ritlecitinib in a heterogeneous cohort of alopecia areata patients and identify response in the scalp as well as lashes, brows, and nails, and clinical predictors of early treatment response. METHODS: We conducted a single-center retrospective cohort study of consecutive patients receiving ritlecitinib 50 mg daily for ≥12 weeks. Disease severity was assessed at baseline and weeks 4, 8, 12, 24, and 36. Treatment-emergent adverse events were systematically recorded. Multivariate logistic regression models assessed the link between treatment response and clinical predictors. RESULTS: The cohort comprised 89 patients (mean age 25.6 ± 13.9 years; 69.7% female). Efficacy outcomes demonstrated temporal progression. The therapeutic efficacy observed in eyelashes, eyebrows, and nails paralleled that of the scalp. Multivariate analysis identified prior Janus kinase inhibitor exposure as an independent predictor of reduced early response. Ritlecitinib demonstrated a favorable safety profile, with no serious adverse events reported throughout the study period. LIMITATIONS: A single-center and Chinese-limited cohort. CONCLUSION: Prior Janus kinase inhibitor exposure is a significant factor influencing early treatment response. Responses of lashes, brows, and nails were similar to the scalp.
引用
- Huang J, Jian J, Li M, et al. Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors. J Am Acad Dermatol. 2025. PMID: 40669542. doi:10.1016/j.jaad.2025.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。